PRECIGEN, INC. Accounts Receivable, Allowance for Credit Loss, Recovery
PRECIGEN, INC. (PGEN) reported Accounts Receivable, Allowance for Credit Loss, Recovery of $1.00 thousand for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-11.
Discontinued › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries · last filed 2020-05-11
- PRECIGEN, INC. accounts receivable, allowance for credit loss, recovery for the quarter ending 2020-03-31 was $1.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Recovery 3 month |
|---|---|
| 2020-03-31 | $1.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |